FDA approvals in October
Company | Drug | Indication |
Astellas Pharma Inc. (Tokyo) and Pfizer Inc. (New York) | Xtandi | Metastatic castration-resistant prostate |
Eli Lilly and Co. (Indianapolis) | Lartruvo | Soft tissue sarcoma |
Genentech Inc. (South San Francisco) | Lucentis | Wet age-related macular degeneration |
Genentech Inc. (South San Francisco; unit of Roche Holdings AG) | Tecentriq | Metastatic non-small-cell lung cancer |
Janssen Pharmaceuticals Inc. (Raritan, N.J.) | Xarelto | Atrial fibrillation |
Ligand Pharmaceuticals Inc. (San Diego) and Lundbeck A/S (Copenhagen) | Carnexiv | Seizures |
Merck & Co Inc. (Kenilworth, N.J.) | Keytruda | Non-small-cell lung cancer (NSCLC) |
Merck & Co. Inc. (Kenilworth, N.J.) | Zinplava | Clostridium difficile infection |
Orexo AB (Uppsala, Sweden) | Zubsolv | Opioid dependence |
Protein Sciences Corp. (Meriden, Conn.) | Flublok | Influenza |
Roche Holding AG (Basel, Switzerland) | Ventana | Metastatic non-small-cell lung cancer |